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Abstract
Background: In southern Europe, the risk of cancer in patients with end-stage kidney disease receiving dialysis has
not been well quantified. The aim of this study was to assess the overall pattern of risk for de novo malignancies
(DNMs) among dialysis patients in the Friuli Venezia Giulia region, north-eastern Italy.
Methods: A population-based cohort study among 3407 dialysis patients was conducted through a record linkage
between local healthcare databases and the cancer registry (1998–2013). Person-years (PYs) were calculated from
30 days after the date of first dialysis to the date of DNM diagnosis, kidney transplant, death, last follow-up or
December 31, 2013, whichever came first. The risk of DNM, as compared to the general population, was estimated
using standardized incidence ratios (SIRs) and 95% confidence intervals (CIs).
Results: During 10,798 PYs, 357 DNMs were diagnosed in 330 dialysis patients. A higher than expected risk of 1.3-
fold was found for all DNMs combined (95% CI: 1.15–1.43). The risk was particularly high in younger dialysis patients
(SIR = 1.88, 95% CI: 1.42–2.45 for age 40–59 years), and it decreased with age. Moreover, significantly increased DNM
risks emerged during the first 3 years since dialysis initiation, especially within the first year (SIR = 8.52, 95% CI: 6.89–
10.41). Elevated excess risks were observed for kidney (SIR = 3.18; 95% CI: 2.06–4.69), skin non-melanoma (SIR = 1.81,
95% CI: 1.46–2.22), oral cavity (SIR = 2.42, 95% CI: 1.36–4.00), and Kaposi’s sarcoma (SIR = 10.29, 95% CI: 1.25–37.16).
Conclusions: The elevated risk for DNM herein documented suggest the need to implement a targeted approach
to cancer prevention and control in dialysis patients.
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Background
Patients receiving renal replacement therapies (RRT) are
known to be at higher risk of cancer than the corre-
sponding general population [1–3]. Although some ma-
lignancies diagnosed in dialysis patients or after kidney
transplant (KT) share similar risk factors (e.g., hepatitis
B virus infection for liver cancer), the magnitude and
pattern of increased risks substantially vary according to
individual and clinical characteristics and to the modal-
ity of RRT [4].
It is well known that emerging techniques and advances
in dialysis technology have led to significant improve-
ments in patients’ life span. Due to increased survival, ma-
lignant neoplasms have become an increasingly relevant
health issue in the dialysis population [5]. Previous studies
have provided convincing evidence of an increased risk of
certain cancer types, such as kidney, thyroid, and bladder
cancer [1, 3, 6, 7], possibly related to side effects of kidney
failure, including the prolonged uremic state, the presence
of chronic infection and inflammation, a weakened im-
mune system, nutritional deficiencies, and impaired mech-
anisms of DNA repair [8].
The investigation of the pattern of cancer risk in dialysis
patients is crucial for planning primary and secondary
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cancer prevention strategies. The increased risk of cancer
in dialysis patients has been well documented in Asia [3,
6], United States [7], Australia/New Zealand [2], and
northern Europe [9]. Conversely, less evidence has been
accumulated in southern European countries, such as
Italy, where end-stage kidney disease (ESKD) patients
represent about 0.1% of the general population [10], and
only a small study has been published in the international
literature [11].
In this population-based investigation, we assessed the
risk and spectrum of de novo malignancies (DNMs)
among dialysis patients as compared to the correspond-
ing general population.
Methods
A population-based cohort study was conducted using
information ascertained through a record linkage pro-
cedure from three health-related databases, which cover
the totality of the population in the Friuli Venezia Giulia
region (1,227,000 inhabitants): 1) the health information
system, which provides personal (e.g., sex, birthdate,
residence, and vital status) and medical care data (e.g.,
hospital discharge, outpatient care, and pharmaceutical
health care); 2) the renal registry database, which in-
cludes information about patients who underwent at
least two dialytic sessions (either peritoneal dialysis or
hemodialysis) per week for at least 90 days; 3) the
population-based cancer registry, which collects data on
all new cases of cancer occurring among the population
living in the Friuli Venezia Giulia region. The cancer
registry started collecting data on new cancer diagnoses
in the resident population in January 1995. For the aims
of this analysis, and to guarantee the highest complete-
ness and accuracy of information, data from these three
databases were linked only to the concurrently available
period, i.e., 1998–2013.
For the aim of this study, the analysis was restricted to
dialysis patients residing in the Friuli Venezia Giulia re-
gion between 1998 and 2013 and aged 40 years or older
at their first dialysis. We focused on dialysis patients
aged ≥40 years, because this age group covered 95% of
all patients who had started their first dialysis between
1998 and 2013 and 99% of all cancer diagnoses in this
population. Excluded from the analysis were subjects
who met at least one of the following conditions: (i) KT
before dialysis (N = 709); (ii) residence outside the Friuli
Venezia Giulia region during the dialysis, or missing in-
formation on residence (N = 113); (iii) follow-up shorter
than 30 days (N = 22). Accordingly to these criteria, 3407
dialysis patients represented our study population.
Cancer diagnoses were coded according to the Inter-
national Classification of Disease, 9th revision (ICD-9).
Cancer diagnoses done by autopsy only (i.e., post-mortem
diagnoses; n = 12) were not considered in this study
because of lack of completeness of this information during
the whole registration period. Multiple primary tumours
were included in the site-specific analyses, while for pa-
tients diagnosed with more than one DNM within the
same ICD-9 group (e.g., colon, rectum, and anus ICD-9
codes: 153–154), only the first one was considered.
Person-years at risk were calculated from 30 days after
the date of first dialysis to the date of DNM diagnosis,
to the date of KT, to the date of death, to end of
follow-up or to December 31, 2013 (i.e., censored cases),
whichever came first. We excluded from the analysis the
first 30 days of follow-up in order to reduce prevalent
DNMs. After a DNM diagnosis, patients did not contrib-
ute any longer to person-time at risk for that specific
cancer site/type. Conversely, those patients continued to
be at risk of other cancer sites/types in the specific ana-
lyses. Patients with a history of cancer prior to their first
dialysis were not considered eligible to contribute to
person-time at risk for that specific cancer site/type.
The cumulative cancer incidence by time since first
dialysis and cancer site/type was estimated using a com-
peting risk approach with nonparametric estimators
[12], taking into account death as a competing event.
Standardized incidence ratios (SIRs) were estimated as
the ratio between the observed number of cancer cases
among the 3407 cohort members and the expected
number of cancer cases among the general population of
the Friuli Venezia Giulia region. According to a standard
procedure [13–15], the expected number of cases was
computed by multiplying the person-years at risk among
the 3407 dialysis patients with the sex- and age-adjusted
cancer incidence rates in the general population of the
Friuli Venezia Giulia region derived from the local
population-based cancer registry. Incidence rates for the
general population were computed using, as numerator,
the observed number of cancer cases, and, as denomin-
ator, the average resident population of same sex and
age, as a proxy of person-years at risk.
SIRs for all cancers combined were also estimated
according to sex, age at first dialysis (40–59, 60–74, ≥75
years), calendar period at first dialysis (1998–2001,
2002–2005, 2006–2009, 2010–2013), follow-up time
(< 1, 1 to < 2, 2 to < 3, 3 to < 5, ≥5 years), and dialysis
modality (haemodialysis, peritoneal dialysis, both
haemodialysis and peritoneal dialysis). Corresponding
95% confidence intervals (CIs) for SIRs were com-
puted assuming a Poisson distribution [13].
Results
The 3407 dialysis patients were followed up for a total of
10,798 person-years (Table 1), with a median follow-up
time of 2.3 years (interquartile range, IQR: 1.0–4.5 years).
Most of these 3407 patients were males (62.4%), aged
between 60 and 74 years at first dialysis (42.6%; median
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age: 70 years; IQR: 61–77 years), and were treated with
haemodialysis (83.9%). More than one third underwent
dialysis between 1998 and 2001 (35.5%). During the
period of observation, 357 DNMs were diagnosed in 330
dialysis patients (9.7%) of whom, 25 had more than one
DNM.
The cumulative incidence of all DNMs combined
steadily increased with time since beginning of dialysis,
reaching 9.8% after 5 years and 13.9% after 10 years
(Fig. 1). A similar pattern emerged after the exclusion of
non-melanoma skin cancers (NMSC), with 5- and
10-year cumulative risks equal to 8.9% and 12.8%,
respectively.
Starting at 40–44 years, the age-specific incidence rates
for de novo malignancies observed among dialysis pa-
tients steadily increased from 670 per 100,000 PYs to
3965 per 100,000 PYs among those aged 85 years and
older (Fig. 2). In dialysis patients, incidence rates were
consistently higher than those in the general population
of the Friuli Venezia Giulia region, even though these
differences decreased with increasing age.
Considering all DNMs combined, a 1.3-fold higher risk
was found in dialysis patients than in the corresponding
general population (95% CI: 1.15–1.43) (Table 2). The
subgroup analysis showed similar SIRs for both sexes
(SIR = 1.29, 95% CI: 1.14–1.46 in males and SIR = 1.27,
95% CI: 1.01–1.57 in females). Furthermore, the risk of
DNM was particularly high in younger dialysis patients
(SIR = 1.88, 95% CI: 1.42–2.45 for age 40–59 years) and
decreased with age. Elevated excess risks were also ob-
served during the first 3 years since dialysis initiation, es-
pecially within the first year (SIR = 8.52, 95% CI: 6.89–
10.41). When comparing the risk of DNM according to
the modality of dialysis, the SIRs were 1.26 (95% CI:
1.12–1.42) in patients treated with haemodialysis and
1.78 (95% CI: 0.95–3.04; based on 13 observed cases of
DNMs) in those treated with peritoneal dialysis.
Table 3 lists the SIRs for specific DNMs with at least
two observed cases. When considering all cancer types/
sites other than NMSC, a 1.2-fold elevated cancer risk
emerged, as compared to the general population (95%
CI:1.03–1.32). Statistically significant increased risks
were documented for NMSC (SIR = 1.81; 95% CI: 1.46–
2.22), cancers of kidney (SIR = 3.18; 95% CI: 2.06–4.69),
oral cavity (SIR = 2.42, 95% CI: 1.36–4.00), and Kaposi’s
sarcoma (SIR = 10.29, 95% CI: 1.25–37.16).
Discussion
The findings from this population-based cohort study
conducted in north-eastern Italy showed that the cumu-
lative cancer risk of dialysis patients reached about 14%
after 10 years of follow-up. This observation corre-
sponded to an overall 1.3-fold higher risk of DNM, as
compared to the general population. Significantly in-
creased cancer risks were seen for younger patients, and
within the first three years of dialysis, as well as for sev-
eral cancer sites/types, including kidney, oral cavity,
NMSC, and Kaposi’s sarcoma.
Several studies have looked at the relationship between
dialysis and cancer incidence, yielding overall estimates
of excess cancer risk that were super-imposable to those
reported in the present investigation [2, 3, 14]. Notably,
results from a recent meta-analysis of population-based
cohort studies showed that, in comparison with the
Table 1 Distribution of 3407 dialysis patients by selected
characteristics. Friuli Venezia Giulia, north-eastern Italy,
1998–2013
All patients
No. (%)
Sex
Male 2126 (62.4)
Female 1281 (37.6)
Age at first dialysis (years)
40–59 746 (21.9)
60–74 1452 (42.6)
≥ 75 1209 (35.5)
Median (Interquartile Range) 70 (61–77)
Calendar year at first dialysis
1998–2001 1208 (35.5)
2002–2005 674 (19.8)
2006–2009 802 (23.5)
2010–2013 723 (21.2)
Dialysis modality
Haemodialysis 2858 (83.9)
Peritoneal dialysis 201 (5.9)
Both haemodialysis and peritoneal dialysis 348 (10.2)
Follow-up (years)
< 1 867 (25.4)
1- < 2 674 (19.8)
2- < 3 539 (15.8)
3- < 5 632 (18.6)
≥ 5 695 (20.4)
Median (Interquartile Range) 2.3 (1.0–4.5)
Total person-years 10,798
Patient with de novo malignancies during dialysis
No 3077 (90.3)
Yes 330 (9.7)
No. of de novo malignancies during dialysis
1 305 (92.4)
2 23 (7.0)
3 2 (0.6)
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general population, the pooled SIRs for DNM in dialysis
patients including or excluding NMSC were 1.40 (95%
CI: 1.36–1.45) and 1.35 (95% CI: 1.23–1.50), respectively
[16]. To the best of our knowledge, only one study, car-
ried out in Denmark, reported no evidence of a statisti-
cally significant increased risk of cancer after excluding
NMSC (SIR = 1.16, 95% CI: 0.92–1.45) [15].
In the subgroup analyses, we found increased cancer
risks that were in line with previous studies carried out in
other industrialized countries [1, 3, 17]. Our results
showed that the excess risk of cancer was higher in
younger dialysis patients, while it declined with increasing
age up to 75 years. Accordingly, a multicenter cohort
study reported a high excess risk in the youngest age
group (i.e., < 45 years at dialysis), which became lower in
patients older than 65 years [14]. This age-related pattern
may have different explanations. Firstly, the enhanced risk
in younger patients is largely attributable to the low can-
cer incidence rates among young people in the general
population. Secondly, younger patients may be affected by
more serious virus-related malignancies against which
their immune defenses, already compromised because of
Fig. 1 Cumulative cancer incidence by time since first dialysis. Friuli Venezia Giulia, north-eastern Italy, 1998–2013
Fig. 2 Age-specific incidence rates for de novo malignancies observed in dialysis patients and in the general population of Friuli Venezia Giulia
region. Friuli Venezia Giulia, north-eastern Italy, 1998–2013
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the uremic state, tend to be lacking, compared to older
people [3, 18]. Thirdly, the presence of ESKD, comorbidi-
ties and frailty could lead elderly dialysis patients to die
from other chronic illnesses, such as cardiovascular dis-
eases, before the development of cancer. Thus, the dis-
crepancy in cancer risk may disappear with increasing age.
We observed an elevated cancer risk among both male
and female patients. A large international collaborative
study reported that the overall risk for cancer was higher
in females than in males during dialysis [1], but other in-
vestigations have reported contradictory findings [19].
Subgroup analysis by follow-up time showed that the
risk of DNM was highest within the first year after dialy-
sis initiation and decreased proportionally with the dur-
ation of dialysis. Similar figures were found in other
investigations [1, 3, 17], with the exception of a
large-scale cohort study, which reported the highest can-
cer risk after 4 years following dialysis initiation [5]. The
increased risk of cancer in the first year of dialysis may
be partially explained by presence of malignancies,
without clinical signs, prior to RRT. Indeed, closer med-
ical surveillance of chronic dialysis patients may have re-
sulted in greater detection of tumors.
The analysis according to dialysis modality was limited
because of the small number of DNMs in patients re-
ceiving peritoneal dialysis (i.e., n = 13 DNMs). Nonethe-
less, we documented a statistically significant increased
risk of cancer in patients receiving haemodialysis, and
an excess risk of borderline statistical significance in the
remaining patients. To the best of our knowledge, only
one recent investigation compared the two groups dir-
ectly, showing no significant differences in cancer risk
[20].
The present study also highlighted a strongly elevated
risk of site-specific cancers. In accordance with other
studies [1–3, 14, 17], a high risk was observed for kidney
cancer, probably attributable to the nature of chronic
kidney disease (CKD), related urological anomalies or
the occurrence of acquired cystic kidney disease [21]. In
contrast with other studies [16], we did not find a high
Table 2 Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) in dialysis patients for all de novo malignancies
(DNMs), by selected subgroups. Friuli Venezia Giulia, north-eastern Italy, 1998–2013
Totala
Obs. Exp. SIR (95% CI)
All 330 256.6 1.29 (1.15–1.43)
Sex
Male 246 190.5 1.29 (1.14–1.46)
Female 84 66.2 1.27 (1.01–1.57)
Age at first dialysis (years)
40–59 56 29.7 1.88 (1.42–2.45)
60–74 176 131.0 1.34 (1.15–1.57)
≥ 75 98 95.9 1.02 (0.83–1.24)
Calendar year at first dialysis
1998–2001 136 106.2 1.28 (1.07–1.52)
2002–2005 79 63.3 1.25 (0.99–1.56)
2006–2009 76 60.6 1.25 (0.99–1.58)
2010–2013 39 26.6 1.47 (1.04–2.00)
Dialysis modality
Haemodialysis 279 221.7 1.26 (1.12–1.42)
Peritoneal dialysis 13 7.3 1.78 (0.95–3.04)
Both haemodialysis and peritoneal dialysis 38 27.7 1.37 (0.97–1.88)
Follow-up (years)
< 1 95 11.2 8.52 (6.89–10.41)
1- < 2 52 24.2 2.15 (1.61–2.82)
2- < 3 48 32.2 1.49 (1.10–1.97)
3- < 5 56 62.0 0.90 (0.68–1.17)
≥ 5 79 127.1 0.62 (0.49–0.77)
aFor patients diagnosed with more than one DNM, only the first one was considered; Obs., observed number of cancer cases; Exp., expected number of
cancer cases
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risk of bladder cancer, which is strongly associated to
several diseases that cause ESKD.
Our estimate of Kaposi’s sarcoma risk was similar to
the findings from a large population-based cohort study
[22]. The elevated excess risk emerged for Kaposi’s sar-
coma is consistent with the evidence that the uremic im-
mune dysfunction status of dialysis patients exposes
them to be susceptible to viruses, such as Kaposi’s
sarcoma-associated herpes virus (KSHV). Moreover, the
prevalence of KSHV has been reported to be higher in
some Mediterranean countries, particularly in Italy [23,
24]. Accordingly, the high excess risk found for cancers
of oral cavity provided further support to the poor im-
mune control of known oncogenic viruses in the ESKD
population. Indeed, previous studies have shown higher
risks of tongue or mouth cancers [22], which are known
to be associated with human papillomavirus. Unfortu-
nately, due to the low number of observed cases in the
present investigation, we could not evaluate the SIRs for
specific oral cavity subtypes.
NMSC was the most common DNM diagnosed among
dialysis patients. Although only a few studies have inves-
tigated NMSC during dialysis, our findings confirmed
prior evidence [25]. A recent Asian study reported that
dialysis patients with uremic pruritus carried a higher
risk of NMSC than those without, suggesting that the
synergic effect of sun exposure and uremia could be re-
sponsible for the carcinogenesis of NMSC [25].
The advanced CKD and side effects of decreased renal
function, including impaired function of the immune sys-
tem and of DNA repair mechanisms as well as chronic in-
fections and inflammations, have been proposed as
Table 3 Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) in dialysis patients for selected de novo malignancies
(DNMs). Friuli Venezia Giulia, north-eastern Italy, 1998–2013
Totala
Cancer type/site ICD-9 codes Obs. Exp. SIR (95% CI)
All but skin non-melanomab 249 213.7 1.17 (1.03–1.32)
Skin non-melanoma 173 93 51.3 1.81 (1.46–2.22)
Prostate 185 35 39.5 0.89 (0.62–1.23)
Trachea, bronchus, and lung 162 31 28.4 1.09 (0.74–1.55)
Colon, rectum, and anus 153, 154 27 31.7 0.85 (0.56–1.24)
Kidney 189 25 7.9 3.18 (2.06–4.69)
Bladder 188 16 17.0 0.94 (0.54–1.52)
Oral cavity 140–149 15 6.2 2.42 (1.36–4.00)
Stomach 151 14 11.6 1.20 (0.66–2.02)
Liver 155 14 9.2 1.53 (0.83–2.56)
Female breast 174 13 14.9 0.81 (0.42–1.41)
Melanoma 172 9 5 1.81 (0.83–3.43)
Pancreas 157 7 7.5 0.93 (0.38–1.93)
Larynx 161 7 3.4 2.03 (0.82–4.18)
Other and ill-defined sites 195 7 1 7.31 (2.94–15.07)
Malignant neoplasm without site specification 199 7 3.8 1.86 (0.75–3.84)
Multiple myeloma 203 5 2.9 1.72 (0.56–4.02)
Leukemia 204–208 4 4.2 0.95 (0.26–2.43)
Corpus uteri 182 4 2.1 1.94 (0.53–4.96)
Pleura 163 2 1.8 1.11 (0.13–4.00)
Other and ill-defined sites within the respiratory system 165 2 0.6 3.14 (0.38–11.33)
Connective and other soft tissue 171 2 1.1 1.90 (0.23–6.87)
Kaposi’s sarcoma 176 2 0.2 10.29 (1.25–37.16)
Uterus, unspecified 179 2 0.3 7.0 (0.85–25.30)
Thyroid gland 193 2 1.4 1.39 (0.17–5.01)
Non-Hodgkin lymphoma 200,202 2 6.6 0.30 (0.04–1.10)
aThe sums can exceed the total because some patients were diagnosed with more than one malignancy. For patients diagnosed with more than one DNM within
the same ICD-9 group (e.g., oral cavity ICD-9 codes: 140–149; leukemia ICD-9 codes: 204–208) only the first one was considered; bIt includes sites/types with < 2
observed cases, which were not shown in table; Obs., observed number of cancer cases; Exp., expected number of cancer cases
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potential promoting factors of cancer [22, 26]. To this
regard, the higher risks found in the present study
are consistent with the evidence that direct carcino-
genic effects of factors related to ESKD are mediated
by dialysis treatments [2]. Previous studies have pro-
vided limited support to the fact that dialysis may it-
self increase the risk of cancer [4]. However, it may
prolong pre-RRT carcinogenic exposure since it nei-
ther completely replaces renal function nor reverses
kidney disease [2].
Some limitations of our study are worth noticing. First,
as for most studies [16], information about patients’ co-
morbidities -which are highly prevalent in this popula-
tion- as well as information about etiology for ESKD or
lifestyle habits (e.g., smoking, alcohol consumption, or
sun exposure) are not routinely collected in the renal
registry of the Friuli Venezia Giulia region. Conse-
quently, we could not evaluate their potential confound-
ing effect on the occurrence of cancer in dialysis
population. However, this lack of information had lim-
ited impact on our aim of quantifying the excess risk of
cancer among dialysis patients, in comparison with the
corresponding general population. Second, we could not
exclude the possibility of overestimation of cancer inci-
dence, as a result of misclassification of prevalent cases
as incident ones. However, to minimize this problem we
excluded from the analysis the first 30 days of dialysis. A
longer lag-time could have been considered between the
occurrence and diagnosis of cancer, as we observed the
highest excess risk of cancer within the first year. Never-
theless, a sensitivity analysis performed excluding the
first 90 days of follow-up showed similar results. Third,
the relatively small size of our cohort limited the study
power to assess the excess risk of cancer for specific can-
cer sites/types. Finally, subgroup analysis should be
interpreted with caution as the general population can-
not be stratified by age at first dialysis, time on dialy-
sis, dialysis modality, and calendar period at first dialysis.
As most studies [16], the expected number of cases in
each subgroup was calculated according to the incidence
rates computed among the average population of Friuli
Venezia Giulia region used for the non-stratified ana-
lysis. Notwithstanding such limitations, this population-
based study represents the largest cohort to provide an
overall picture of cancer risk among dialysis patients in
southern Europe. One of the strengths of this study is
the complete coverage of Friuli Venezia Giulia dialysis
patients thanks to the use of population-based adminis-
trative data, which allows a comprehensive assessment
of the health status of the whole population of the Friuli
Venezia Giulia region. In addition, the use of incidence
data collected by the same population-based cancer
registry, ensures high standards in terms of quality and
completeness of cancer reporting.
Conclusions
Our findings put in evidence the need of monitoring the
cancer burden among ESKD patients undergoing dialy-
sis. The increased risks documented in relation to spe-
cific cancer sites and in younger patients suggest that
targeted approach to cancer screening need to be imple-
mented in the dialysis population. The link between
renal function and cancer risk, and the detection of pos-
sible mechanisms through which renal impairment can
modulate cancer risk remain a topic of great scientific
interest.
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